Novi Chandra Imelda, - and Fadil Baktir, - and Fidiana, - and Hanik Badriyah Hidayati, - (2018) Updates in the management of Guillain Barre Syndrome. Anaesth, Pain & Intensive Care, 22 (Supp1). pp. 54-57. ISSN 16078322
Text (Artikel)
Bukti C-05 GBS.pdf Download (296kB) |
|
Text (Peer Review)
Bukti C-05 Peer Review.pdf Download (1MB) |
|
Text (Similarity)
Bukti C-05 GBS.pdf Download (1MB) |
|
Text (Bukti Korespondensi)
3.pdf Download (142kB) |
Abstract
Barré and Strohl in 1916. Although GBS has a good prognosis (5% mortality rate), about 10% of patients experience serious disability one year after the start of neurological onset. Recent research of GBS shows that the process involves a number of subtypes with different immunological mechanism and a spectrum of clinical syndrome of acute inflammatory neuropathy. Antibodies against peripheral nerve gangliosides and their own complements are recognized as an important mechanism of nerve damage in GBS. Pharmacokinetics of intravenous immunoglobulin (IVIg) therapy and other related factors that influence prognosis has been researched. In order to investigate the possible role of complement inhibition in GBS management, new studies will be conducted. The management of GBS should be provided in appropriate hospital units, with specialist teams, intensive care and rehabilitation facilities as essential parts. This article aims to provide updated management of GBS.
Item Type: | Article | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Uncontrolled Keywords: | Guillain-Barre syndrome, GBS, Management, Immunotherapy | ||||||||||
Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine |
||||||||||
Divisions: | 01. Fakultas Kedokteran > Ilmu Penyakit Saraf Artikel Ilmiah > SCOPUS INDEXED JOURNAL |
||||||||||
Creators: |
|
||||||||||
Depositing User: | arys fk | ||||||||||
Date Deposited: | 09 Apr 2021 06:38 | ||||||||||
Last Modified: | 08 Mar 2022 03:27 | ||||||||||
URI: | http://repository.unair.ac.id/id/eprint/105198 | ||||||||||
Sosial Share: | |||||||||||
Actions (login required)
View Item |